# OnCo record ipmn-associated-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/ipmn-associated-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "ipmn-associated-carcinoma" ;
  schema:name "Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)"@en ;
  schema:alternateName "Invasive carcinoma arising in an IPMN (tubular or colloid type; treated as ductal PDAC)"@en, "Invasive carcinoma arising in an IPMN (tubular or colloid type; 10 percent of resections; staged and treated as ductal adenocarcinoma)"@en, "IPMN with associated invasive carcinoma"@en, "Invasive IPMN"@en, "IPMN-associated invasive adenocarcinoma"@en, "IPMN-derived pancreatic cancer"@en ;
  schema:description "IPMN-associated carcinoma is pancreatic cancer that has grown out of a mucus-producing cyst in the pancreatic duct. Because the cyst is often being watched, the cancer is found smaller and earlier, and about four in ten patients are alive five years after surgery against two in ten for ordinary pancreatic cancer; the advantage belongs to the colloid type, not the tubular type."@en ;
  schema:url <https://onco.cc/cancers/ipmn-associated-carcinoma/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Intraductal_papillary_mucinous_neoplasm> ;
  schema:citation <https://doi.org/10.1097/sla.0b013e3181cf8a19>, <https://doi.org/10.1136/gut.2010.232272>, <https://doi.org/10.1097/sla.0b013e318214bcb4>, <https://doi.org/10.1097/pas.0000000000000533>, <https://doi.org/10.1111/his.13975> ;
  onco:tag "gi", "pancreatic", "subtype-page" ;
  onco:related <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/ipmn-cystic-precursors/>, <https://onco.cc/cancers/pancreatic-colloid-carcinoma/>, <https://onco.cc/cancers/mcn-associated-carcinoma/>, <https://onco.cc/cancers/resectable-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/pancreatic-surveillance/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/endoscopic-ultrasound-systems/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/smad4/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/nalirifox/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pancreatic-cancer-signalling/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:terms <https://onco.cc/terms/pancreatic-cyst-high-risk-stigmata/>, <https://onco.cc/terms/panin/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/distal-pancreatectomy/>, <https://onco.cc/terms/resection-margins/>, <https://onco.cc/terms/tumour-grade/> ;
  onco:standardOfCare <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/distal-pancreatectomy/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/technologies/pancreatic-surveillance/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/nalirifox/> .